Literature DB >> 15784307

Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa.

Jeom Kyu Lee1, Yeong Seon Lee, Yong Keun Park, Bong Su Kim.   

Abstract

The presence of fluoroquinolone resistance-associated alterations in topoisomerase II and IV were investigated for 103 nfxC-like type Pseudomonas aeruginosa isolates. The most nfxC-like type isolates (98.1%) possessed the substitution of Ile for Thr-83 in GyrA. A single alteration in GyrA (Thr-83-->Ile) was the most frequently detected and the next common alteration was two alterations with Thr-83-->Ile in GyrA and Ser-87-->Leu in ParC. A novel alteration at position Glin-106 of GyrA, which was suggested to be responsible for fluoroquinolone resistance, was identified. Our study revealed that the alterations in GyrB (Glu-468-->Asp) and in ParE (Asp-419-->Asn or Glu-459-->Asp) play a complementary role in the acquisition of resistance to fluoroquinolone. There was a correlation between the ciprofloxacin MIC and the number of resistance-associated alterations in GyrA, GyrB, ParC and ParE of P. aeruginosa isolates.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15784307     DOI: 10.1016/j.ijantimicag.2004.11.012

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  34 in total

Review 1.  In front of and behind the replication fork: bacterial type IIA topoisomerases.

Authors:  Claudia Sissi; Manlio Palumbo
Journal:  Cell Mol Life Sci       Date:  2010-02-18       Impact factor: 9.261

2.  Regional Isolation Drives Bacterial Diversification within Cystic Fibrosis Lungs.

Authors:  Peter Jorth; Benjamin J Staudinger; Xia Wu; Katherine B Hisert; Hillary Hayden; Jayanthi Garudathri; Christopher L Harding; Matthew C Radey; Amir Rezayat; Gilbert Bautista; William R Berrington; Amanda F Goddard; Chunxiang Zheng; Angus Angermeyer; Mitchell J Brittnacher; Jacob Kitzman; Jay Shendure; Corinne L Fligner; John Mittler; Moira L Aitken; Colin Manoil; James E Bruce; Timothy L Yahr; Pradeep K Singh
Journal:  Cell Host Microbe       Date:  2015-08-20       Impact factor: 21.023

3.  A large-scale whole-genome comparison shows that experimental evolution in response to antibiotics predicts changes in naturally evolved clinical Pseudomonas aeruginosa.

Authors:  Samuel J T Wardell; Attika Rehman; Lois W Martin; Craig Winstanley; Wayne M Patrick; Iain L Lamont
Journal:  Antimicrob Agents Chemother       Date:  2019-09-30       Impact factor: 5.191

4.  Quantitative contributions of target alteration and decreased drug accumulation to Pseudomonas aeruginosa fluoroquinolone resistance.

Authors:  Sebastian Bruchmann; Andreas Dötsch; Bianka Nouri; Iris F Chaberny; Susanne Häussler
Journal:  Antimicrob Agents Chemother       Date:  2012-12-28       Impact factor: 5.191

5.  Outbreaks of multidrug-resistant Pseudomonas aeruginosa in community hospitals in Japan.

Authors:  Jun-Ichiro Sekiguchi; Tsukasa Asagi; Tohru Miyoshi-Akiyama; Atsushi Kasai; Yukie Mizuguchi; Minako Araake; Tomoko Fujino; Hideko Kikuchi; Satoru Sasaki; Hajime Watari; Tadashi Kojima; Hiroshi Miki; Keiji Kanemitsu; Hiroyuki Kunishima; Yoshihiro Kikuchi; Mitsuo Kaku; Hiroshi Yoshikura; Tadatoshi Kuratsuji; Teruo Kirikae
Journal:  J Clin Microbiol       Date:  2006-11-22       Impact factor: 5.948

6.  Sublethal ciprofloxacin treatment leads to rapid development of high-level ciprofloxacin resistance during long-term experimental evolution of Pseudomonas aeruginosa.

Authors:  Karin Meinike Jørgensen; Tina Wassermann; Peter Østrup Jensen; Wang Hengzuang; Søren Molin; Niels Høiby; Oana Ciofu
Journal:  Antimicrob Agents Chemother       Date:  2013-06-17       Impact factor: 5.191

Review 7.  Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.

Authors:  Philip D Lister; Daniel J Wolter; Nancy D Hanson
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

8.  Cellular reporter screens for inhibitors of Burkholderia pseudomallei targets in Pseudomonas aeruginosa.

Authors:  Donald T Moir; Ming Di; Richard A Moore; Herbert P Schweizer; Donald E Woods
Journal:  Trans R Soc Trop Med Hyg       Date:  2008-12       Impact factor: 2.184

9.  CrpP Is a Novel Ciprofloxacin-Modifying Enzyme Encoded by the Pseudomonas aeruginosa pUM505 Plasmid.

Authors:  Víctor M Chávez-Jacobo; Karen C Hernández-Ramírez; Pamela Romo-Rodríguez; Rocío Viridiana Pérez-Gallardo; Jesús Campos-García; J Félix Gutiérrez-Corona; Juan Pablo García-Merinos; Víctor Meza-Carmen; Jesús Silva-Sánchez; Martha I Ramírez-Díaz
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

10.  Genome-scale identification method applied to find cryptic aminoglycoside resistance genes in Pseudomonas aeruginosa.

Authors:  Julie M Struble; Ryan T Gill
Journal:  PLoS One       Date:  2009-11-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.